Azalea Therapeutics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $65M

  • Investors
  • 5

Azalea Therapeutics General Information

Description

Operator of a biotechnology platform intended to enable precise genome editing inside the body for disease treatment. The company offers an Enveloped Delivery Vehicle technology that directs CRISPR-Cas9 cargo to specific cells, enabling patients with cancer, autoimmune, and genetic conditions to receive targeted and sustained therapies.

Contact Information

Website
azaleatx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2625 Durant Avenue
  • Berkeley, CA 94720
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Vertical(s)
Corporate Office
  • 2625 Durant Avenue
  • Berkeley, CA 94720
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Azalea Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 30-Oct-2025 $65M Completed Startup
3. Grant Completed Startup
2. Seed Round 01-Jan-2023 $17M $17M Completed Startup
1. University Spin-Out 01-Jan-2023 Completed Startup
To view Azalea Therapeutics’s complete valuation and funding history, request access »

Azalea Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Azalea Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Azalea Therapeutics Patents

Azalea Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236280-A1 In the united states patent and trademark office Pending 05-May-2025
WO-2026178423-A2 T cell-targeted delivery vehicles Pending 20-Feb-2025
WO-2026178423-A3 T cell-targeted delivery vehicles Pending 20-Feb-2025
AU-2022208037-A1 Aav vectors targeting t-cells Pending 14-Jan-2021
AU-2022208037-A9 Aav vectors targeting t-cells Pending 14-Jan-2021
To view Azalea Therapeutics’s complete patent history, request access »

Azalea Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
RA Capital Management Asset Manager Minority
Sozo Ventures Venture Capital Minority
Third Rock Ventures Venture Capital Minority
Yosemite Venture Capital Minority
University of California, Berkeley University
To view Azalea Therapeutics’s complete investors history, request access »

Azalea Therapeutics FAQs

  • When was Azalea Therapeutics founded?

    Azalea Therapeutics was founded in 2023.

  • Where is Azalea Therapeutics headquartered?

    Azalea Therapeutics is headquartered in Berkeley, CA.

  • What industry is Azalea Therapeutics in?

    Azalea Therapeutics’s primary industry is Biotechnology.

  • Is Azalea Therapeutics a private or public company?

    Azalea Therapeutics is a Private company.

  • What is the current valuation of Azalea Therapeutics?

    The current valuation of Azalea Therapeutics is .

  • What is Azalea Therapeutics’s current revenue?

    The current revenue for Azalea Therapeutics is .

  • How much funding has Azalea Therapeutics raised over time?

    Azalea Therapeutics has raised $82M.

  • Who are Azalea Therapeutics’s investors?

    RA Capital Management, Sozo Ventures, Third Rock Ventures, Yosemite, and University of California, Berkeley have invested in Azalea Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process